3 ASX 200 Shares to Buy Now

The following three ASX 200 shares stand out as compelling buys right now backed by resilient business fundamentals and attractive long-term growth prospects.

QBE Insurance Group Limited (ASX: QBE)

QBE Insurance Group Limited (ASX: QBE) has surged 10% over the past month and is one of the best ASX 200 stocks to buy now because of its disciplined underwriting and consistent earnings growth while current market capitalisation is $37.28 billion.
The company made a strong start to FY26 as gross written premium rose 11% from the prior corresponding period or 7% on a constant currency basis while it also reaffirmed guidance for mid-single digit premium growth.

Investment performance also stayed strong because investment income reached approximately US$500 million in the four months to April while funds under management increased to US$36.1 billion and the core fixed income yield improved to 4.1%.

Management has also completed its $450 million share buyback and reiterated confidence in the business outlook while the company invests in digital capabilities and artificial intelligence to improve underwriting along with customer service.

The current partially franked annual dividend yield is 4.37% and QBE expects to sustain an adjusted return on equity of more than 15% over the medium-term alongside continued premium growth which is supported by its disciplined risk management.

ResMed Inc. (ASX: RMD)

ResMed Inc. (ASX: RMD) is one of the best ASX 200 stocks to buy now with a current market capitalisation of $44.18 billion and a price/earnings ratio of 20 as it reported another quarter of strong earnings growth.

The company for the March 2026 quarter reported net revenue of US$1.43 billion which increased 10.8% year-on-year while net income rose 9.2% to US$398.7 million and diluted earnings per share increased to US$2.74 from US$2.48.

Both core business segments supported this performance because Sleep and Breathing Health revenue increased to US$1.26 billion from US$1.13 billion while Residential Care Software revenue grew to US$170.9 million from US$161.2 million.

The company also improved its financial position and ended the quarter with US$1.66 billion in cash and cash equivalents while it generated US$1.35 billion in operating cash flow during the first nine months of FY2026.

ResMed is well positioned to benefit from increasing global awareness of sleep disorders which will support its long-term earnings growth.

Zip Co Limited (ASX: ZIP)

Zip Co Limited (ASX: ZIP) is one of the best ASX 200 stocks to buy now because the company has achieved record profitability with fast transaction growth while its current market capitalisation is almost $4 billion.

The company in the third quarter of FY2026 reported total transaction volume of $4 billion which was up 22.4% year-on-year while record cash EBTDA rose 41.5% to $65.1 million.

The US business remained the main growth driver as revenue increased 43.3% to US$155.5 million while transaction volume grew 43.1% to US$2.12 billion and the company also maintained disciplined credit performance while expanding its merchant network to 93.9 thousand.

Recent developments include the launch of Pay-in-2 in the US while broader AI integration across the business and an ongoing $50 million share buyback programme supported progress and the company ended the quarter with $405.1 million in cash.

Management upgraded FY2026 cash EBTDA guidance to at least $260 million and expects US transaction volume growth of more than 40% with group operating margins above 18% which reflects confidence in future profitable growth.

(Source: Company Announcements)